Medpace Holdings（1MEDP）株式概要メドスペース・ホールディングスは、北米、欧州、アジアで臨床研究をベースとした医薬品・医療機器開発サービスを提供している。 詳細1MEDP ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長3/6過去の実績4/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より12.4%で取引されている 収益は年間8.36%増加すると予測されています 過去1年間で収益は17.5%増加しました 同業他社や業界と比較して、良好な取引価格 リスク分析Italian市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見る1MEDP Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW475,099 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA475,099 investors already sharing narrativesYour Fair Value€Current Price€499.502.7% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-299k4b2016201920222025202620282031Revenue US$4.0bEarnings US$701.8mAdvancedSet Fair ValueView all narrativesMedpace Holdings, Inc. 競合他社Fine Foods & Pharmaceuticals N.T.MSymbol: BIT:FFMarket cap: €194.3mRecordati Industria Chimica e FarmaceuticaSymbol: BIT:RECMarket cap: €10.5bDivi's LaboratoriesSymbol: NSEI:DIVISLABMarket cap: ₹2.1tWuXi Biologics (Cayman)Symbol: SEHK:2269Market cap: HK$155.1b価格と性能株価の高値、安値、推移の概要Medpace Holdings過去の株価現在の株価US$499.5052週高値US$554.2052週安値US$336.70ベータ1.151ヶ月の変化6.19%3ヶ月変化39.64%1年変化31.48%3年間の変化n/a5年間の変化n/aIPOからの変化90.29%最新ニュースRecent Insider Transactions • 3hInsider recently sold €3.9m worth of stockOn the 28th of July, Susan Burwig sold around 8k shares on-market at roughly €527 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €194m more than they bought in the last 12 months.お知らせ • Jul 24Medpace Holdings, Inc. Updates Earnings Guidance for the Year 2026Medpace Holdings, Inc. updated earnings guidance for the year 2026. For the year, the company expects total revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion. The company forecast 2026 net income in the range of $494 million to $514 million. Earnings per diluted share is now expected to be in the range of $17.25 to $17.95.Reported Earnings • Jul 24Second quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025)Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026最新情報をもっと見るRecent updatesRecent Insider Transactions • 3hInsider recently sold €3.9m worth of stockOn the 28th of July, Susan Burwig sold around 8k shares on-market at roughly €527 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €194m more than they bought in the last 12 months.お知らせ • Jul 24Medpace Holdings, Inc. Updates Earnings Guidance for the Year 2026Medpace Holdings, Inc. updated earnings guidance for the year 2026. For the year, the company expects total revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion. The company forecast 2026 net income in the range of $494 million to $514 million. Earnings per diluted share is now expected to be in the range of $17.25 to $17.95.Reported Earnings • Jul 24Second quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025)Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.お知らせ • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026お知らせ • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.Board Change • Apr 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.お知らせ • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026お知らせ • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.Buy Or Sell Opportunity • Mar 12Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.Buy Or Sell Opportunity • Feb 12Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.Board Change • Feb 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Buy Or Sell Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.お知らせ • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold).Recent Insider Transactions • Nov 13Executive Vice President of Operations recently sold €9.4m worth of stockOn the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m.Recent Insider Transactions • Oct 30Executive Vice President of Operations recently sold €1.0m worth of stockOn the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m.Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024)Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.Buy Or Sell Opportunity • Oct 10Now 20% undervaluedOver the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period.お知らせ • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025Recent Insider Transactions • Sep 04Chairman & CEO recently sold €15m worth of stockOn the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m.Recent Insider Transactions • Aug 22Independent Director recently sold €662k worth of stockOn the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months.Recent Insider Transactions • Jul 30Chairman & CEO recently sold €19m worth of stockOn the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.Reported Earnings • Jul 23Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024)Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.お知らせ • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025株主還元1MEDPIT Life SciencesIT 市場7D-5.8%3.9%1.4%1Y31.5%-1.0%23.1%株主還元を見る業界別リターン: 1MEDP過去 1 年間で-1 % の収益を上げたItalian Life Sciences業界を上回りました。リターン対市場: 1MEDP過去 1 年間で23.1 % の収益を上げたItalian市場を上回りました。価格変動Is 1MEDP's price volatile compared to industry and market?1MEDP volatility1MEDP Average Weekly Movement8.4%Life Sciences Industry Average Movement6.2%Market Average Movement4.7%10% most volatile stocks in IT Market8.1%10% least volatile stocks in IT Market2.9%安定した株価: 1MEDPの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1MEDPの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19926,500August Troendlewww.medpace.comメドスペース・ホールディングスは、北米、欧州、アジアにおいて、臨床研究ベースの医薬品・医療機器開発サービスを提供している。同社は、様々な治療分野において、第Ⅰ相から第Ⅳ相までの臨床開発プロセスをサポートする一連のサービスを提供している。製薬、バイオテクノロジー、医療機器業界に臨床開発サービスを提供し、開発計画設計、コーディネートされた中央研究所、プロジェクト管理、薬事業務、臨床モニタリング、データ管理・分析、ファーマコビジランス新薬承認申請、市販後臨床支援サービスを行う。さらに、臨床試験のためのバイオ分析ラボサービス、臨床ヒト薬理学、画像サービス、心電図読影サポートも提供している。メドスペース・ホールディングスは1992年に設立され、オハイオ州シンシナティに本社を置いている。もっと見るMedpace Holdings, Inc. 基礎のまとめMedpace Holdings の収益と売上を時価総額と比較するとどうか。1MEDP 基礎統計学時価総額€14.16b収益（TTM）€426.28m売上高(TTM)€2.41b32.8xPER（株価収益率5.8xP/Sレシオ1MEDP は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1MEDP 損益計算書（TTM）収益US$2.78b売上原価US$769.32m売上総利益US$2.01bその他の費用US$1.52b収益US$491.50m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）17.61グロス・マージン72.35%純利益率17.67%有利子負債／自己資本比率0%1MEDP の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/30 04:13終値2026/07/30 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medpace Holdings, Inc. 12 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。21 アナリスト機関Eric ColdwellBairdLuke SergottBarclaysSean DodgeBMO Capital Markets Equity Research18 その他のアナリストを表示
Recent Insider Transactions • 3hInsider recently sold €3.9m worth of stockOn the 28th of July, Susan Burwig sold around 8k shares on-market at roughly €527 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €194m more than they bought in the last 12 months.
お知らせ • Jul 24Medpace Holdings, Inc. Updates Earnings Guidance for the Year 2026Medpace Holdings, Inc. updated earnings guidance for the year 2026. For the year, the company expects total revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion. The company forecast 2026 net income in the range of $494 million to $514 million. Earnings per diluted share is now expected to be in the range of $17.25 to $17.95.
Reported Earnings • Jul 24Second quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025)Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.
New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026
Recent Insider Transactions • 3hInsider recently sold €3.9m worth of stockOn the 28th of July, Susan Burwig sold around 8k shares on-market at roughly €527 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €194m more than they bought in the last 12 months.
お知らせ • Jul 24Medpace Holdings, Inc. Updates Earnings Guidance for the Year 2026Medpace Holdings, Inc. updated earnings guidance for the year 2026. For the year, the company expects total revenue in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025 total revenue of $2.53 billion. The company forecast 2026 net income in the range of $494 million to $514 million. Earnings per diluted share is now expected to be in the range of $17.25 to $17.95.
Reported Earnings • Jul 24Second quarter 2026 earnings released: EPS: US$4.31 (vs US$3.16 in 2Q 2025)Second quarter 2026 results: EPS: US$4.31 (up from US$3.16 in 2Q 2025). Revenue: US$707.3m (up 17% from 2Q 2025). Net income: US$121.4m (up 35% from 2Q 2025). Profit margin: 17% (up from 15% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €467, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €547 per share.
New Risk • Jun 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
お知らせ • Jun 17Medpace Holdings, Inc. to Report Q2, 2026 Results on Jul 22, 2026Medpace Holdings, Inc. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026
お知らせ • Jun 06Medpace Holdings, Inc. Announces Appointment of Brad W. Hansman to Executive Vice President, Operations, Effective June 1, 2026Effective June 1, 2026, Medpace Holdings, Inc. appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations. In this role, Mr. Hansman shall perform the functions of the Company’s principal operating officer along with Susan E. Burwig, the Company’s Executive Vice President, Operations. Mr. Hansman joined the Company in April 2011 in Finance & Accounting and held various roles in Finance until July 2015. Since August 2015, Mr. Hansman has held various key leadership roles in operations including Executive Director, Vice President, and Senior Vice President overseeing study start-up, logistics, regulatory affairs, and medical writing. Prior to joining the Company, Mr. Hansman worked for Joseph Decosimo & Company, LLC as an Audit Supervisor from July 2008 to March 2011. Mr. Hansman started his career at Macy’s, Inc. where he held various auditor positions from July 2006 to June 2008. Mr. Hansman received his Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). Mr. Hansman does not hold any public company directorships.
Board Change • Apr 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 23Medpace Holdings, Inc. Provides Earnings Guidance for the Year 2026Medpace Holdings, Inc. provided earnings guidance for the year 2026. For the year, the company forecasts revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income for full year 2026 is forecasted in the range of $487.0 million to $511.0 million. Based on forecasted 2026 revenue of $2.755 billion to $2.855 billion and GAAP net income of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50. This guidance assumes a full year 2026 tax rate of 19.0% to 20.0%, interest income of $27.5 million, foreign exchange rates as of March 31, 2026, and 29.2 million diluted weighted average shares outstanding.
Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to €385. The fair value is estimated to be €496, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.
お知らせ • Mar 25Medpace Holdings, Inc. to Report Q1, 2026 Results on Apr 22, 2026Medpace Holdings, Inc. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026
お知らせ • Mar 17Medpace Holdings, Inc., Annual General Meeting, May 15, 2026Medpace Holdings, Inc., Annual General Meeting, May 15, 2026.
Buy Or Sell Opportunity • Mar 12Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 20% to €376. The fair value is estimated to be €493, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 9.5% per annum over the same time period.
Buy Or Sell Opportunity • Feb 12Now 28% undervalued after recent price dropOver the last 90 days, the stock has fallen 37% to €328. The fair value is estimated to be €453, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 24%. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 9.4% per annum over the same time period.
Board Change • Feb 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 10Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year of 2026Medpace Holdings, Inc. provides earnings guidance for the full year of 2026. For the period, the company expects revenue in the range of $2.755 billion to $2.855 billion, representing growth of 8.9% to 12.8% over 2025 revenue of $2.530 billion. GAAP net income is forecasted in the range of $487.0 million to $511.0 million, diluted earnings per share (GAAP) is forecasted in the range of $16.68 to $17.50.
Board Change • Feb 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Dani Zander was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Buy Or Sell Opportunity • Jan 24Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 7.5% to €473. The fair value is estimated to be €598, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 25%. For the next 3 years, revenue is forecast to grow by 10% per annum. Earnings are also forecast to grow by 10% per annum over the same time period.
お知らせ • Jan 06Medpace Holdings, Inc. to Report Q4, 2025 Results on Feb 09, 2026Medpace Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Feb 09, 2026
New Risk • Nov 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (5.8% average weekly change). Significant insider selling over the past 3 months (€62m sold).
Recent Insider Transactions • Nov 13Executive Vice President of Operations recently sold €9.4m worth of stockOn the 11th of November, Susan Burwig sold around 18k shares on-market at roughly €522 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €17m.
Recent Insider Transactions • Oct 30Executive Vice President of Operations recently sold €1.0m worth of stockOn the 27th of October, Susan Burwig sold around 2k shares on-market at roughly €520 per share. This transaction amounted to 3.0% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €15m. Susan has been a net seller over the last 12 months, reducing personal holdings by €8.1m.
Reported Earnings • Oct 23Third quarter 2025 earnings released: EPS: US$3.95 (vs US$3.11 in 3Q 2024)Third quarter 2025 results: EPS: US$3.95 (up from US$3.11 in 3Q 2024). Revenue: US$659.9m (up 24% from 3Q 2024). Net income: US$111.1m (up 15% from 3Q 2024). Profit margin: 17% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 23Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. provided earnings guidance for the full year 2025. The Company forecasts 2025 revenue in the range of $2.480 billion to $2.530 billion, representing growth of 17.6% to 20.0% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $431.0 million to $439.0 million. Diluted earnings per share (GAAP) is forecasted in the range of $14.60 to $14.86.
Buy Or Sell Opportunity • Oct 10Now 20% undervaluedOver the last 90 days, the stock has risen 59% to €436. The fair value is estimated to be €547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 9.7% per annum. Earnings are also forecast to grow by 8.1% per annum over the same time period.
お知らせ • Sep 24Medpace Holdings, Inc. to Report Q3, 2025 Results on Oct 22, 2025Medpace Holdings, Inc. announced that they will report Q3, 2025 results After-Market on Oct 22, 2025
Recent Insider Transactions • Sep 04Chairman & CEO recently sold €15m worth of stockOn the 2nd of September, August Troendle sold around 37k shares on-market at roughly €408 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €19m. August has been a net seller over the last 12 months, reducing personal holdings by €34m.
Recent Insider Transactions • Aug 22Independent Director recently sold €662k worth of stockOn the 19th of August, Cornelius McCarthy sold around 2k shares on-market at roughly €398 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €19m. Insiders have been net sellers, collectively disposing of €24m more than they bought in the last 12 months.
Recent Insider Transactions • Jul 30Chairman & CEO recently sold €19m worth of stockOn the 28th of July, August Troendle sold around 48k shares on-market at roughly €389 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was August's only on-market trade for the last 12 months.
Reported Earnings • Jul 23Second quarter 2025 earnings released: EPS: US$3.16 (vs US$2.85 in 2Q 2024)Second quarter 2025 results: EPS: US$3.16 (up from US$2.85 in 2Q 2024). Revenue: US$603.3m (up 14% from 2Q 2024). Net income: US$90.3m (up 2.2% from 2Q 2024). Profit margin: 15% (down from 17% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Jul 22Medpace Holdings, Inc. Updates Earnings Guidance for the Full Year 2025Medpace Holdings, Inc. updated earnings guidance for the full year 2025. For the year company expects revenue in the range of $2.420 billion to $2.520 billion, representing growth of 14.7% to 19.5% over 2024 revenue of $2.109 billion. GAAP net income for full year 2025 is forecasted in the range of $405.0 million to $428.0 million. Based on forecasted 2025 revenue of $2.420 billion to $2.520 billion and GAAP net income of $405.0 million to $428.0 million, diluted earnings per share (GAAP) is forecasted in the range of $13.76 to $14.53.
お知らせ • Jun 24Medpace Holdings, Inc. to Report Q2, 2025 Results on Jul 21, 2025Medpace Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Jul 21, 2025
